drugset / Trial / NCT01113931

Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin

NCT01113931

Phase 3 Completed 495 enrolled Warner Chilcott
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Evaluate the clinical efficacy and safety of WC2031 200 mg tablets taken orally once a day for 7 days versus Vibramycin (doxycycline) 100 mg capsules taken orally twice a day for 7 days, for the treatment of uncomplicated urogenital Chlamydia trachomatis infection. Primary efficacy endpoint is microbiological cure at Day 28. Safety assessments are adverse events, changes in vital signs and laboratory test results.

Timeline

Start
2010-04
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 100 mg
Subject Doxycycline Small molecule 200 mg